<DOC>
	<DOCNO>NCT03042780</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety FOLFIRINOX patient gastroenteropancreatic high-grade neuroendocrine carcinoma . This prospective Phase II open-label trial , stratify gastroenteropancreatic high grade neuroendocrine carcinoma participant equally two cohort ( first-line versus beyond first-line ) .</brief_summary>
	<brief_title>FOLFIRINOX Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<mesh_term>Carcinoma , Islet Cell</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Histologically cytologically confirm neuroendocrine carcinoma gastrointestinal ( GI ) tract . Potential participant unknown origin neuroendocrine carcinoma gastroenteropancreatic origin suspect ( per pathologist investigator discretion ) eligible study . Tumors must Ki67 index great 20 % and/or &gt; 20 mitotic figures/10 highpower field . Must metastatic disease . Must measurable disease , define Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 . Any line treatment ( first line versus beyond first line ) . Age &gt; 18 year . Life expectancy great 12 week . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 . Must adequate organ marrow function . Ability understand willingness sign write informed consent document . Have chemotherapy radiotherapy within 3 week prior enter study . Receiving investigational agent . Untreated brain meningeal metastasis . Prior treatment 5fluorouracil ( 5FU ) , irinotecan oxaliplatin . Pretreatment peripheral neuropathy great grade 1 per CTCAE , version 4.0 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . A secondary primary cancer ( exclude baso/squamous cell carcinoma skin ) within 1 year . Active viral hepatitis autoimmune hepatitis . The workup confirm active hepatitis autoimmune hepatitis do clinical suspicion base investigator discretion . Potential participant childbearing potential willing use adequate contraception precaution study 3 month stop study chemotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Gastroenteropancreatic neuroendocrine carcinoma ( GEP-NECs )</keyword>
	<keyword>Metastatic</keyword>
	<keyword>High grade</keyword>
	<keyword>Pancreas</keyword>
	<keyword>Neuroendocrine carcinoma gastrointestinal tract</keyword>
</DOC>